Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

Funding is awarded following successful completion of IND-enabling studies and clinical study authorization  USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical study Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products.